Sanofi (NASDAQ:SNY) Issues Earnings Results

Sanofi (NASDAQ:SNY) issued its quarterly earnings data on Thursday. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05, Zacks reports. The business had revenue of $10.75 billion for the quarter, compared to the consensus estimate of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 38.98%. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.95 EPS.

Sanofi Stock Down 1.3 %

Sanofi stock traded down $0.70 during mid-day trading on Friday, reaching $52.40. The stock had a trading volume of 1,994,568 shares, compared to its average volume of 2,357,098. The company has a market capitalization of $132.72 billion, a price-to-earnings ratio of 26.33, a PEG ratio of 1.63 and a beta of 0.59. The company has a 50-day moving average price of $49.21 and a two-hundred day moving average price of $48.69. Sanofi has a one year low of $42.63 and a one year high of $55.72. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on SNY. Argus upped their target price on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research report on Friday. StockNews.com raised shares of Sanofi from a “buy” rating to a “strong-buy” rating in a research report on Friday. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.